Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

CompletedOBSERVATIONAL
Enrollment

386,301

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

July 22, 2025

Conditions
Type 2 DiabetesCardiac Disease
Interventions
DRUG

Glucagon like peptide 1 receptor agonist

Patients in the data who filled a glucagon-like peptide-1 receptor agonist medication

DRUG

Sodium-glucose cotransporter 2 inhibitor

Patients in the data who filled a sodium-glucose cotransporter 2 inhibitor

DRUG

Dipeptidyl Peptidase 4 Inhibitor

Patients in the data who filled a dipeptidyl peptidase-4 inhibitor

DRUG

Sulfonylurea

Patients in the data who filled a sulfonylurea

Trial Locations (1)

55905

Mayo Clinic Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Mayo Clinic

OTHER

NCT05214573 - Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk | Biotech Hunter | Biotech Hunter